Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

17.57 +0.07 (+0.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
A Preview Of Travere Therapeutics's Earnings
Via Benzinga
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker. 
Via Benzinga
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
Via Benzinga
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Analyst Ratings For Travere Therapeutics
Via Benzinga
Expert Ratings For Travere Therapeutics
Via Benzinga
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
The company could soon ask for approval of its only drug, Filspari, in a second disease. 
Via Investor's Business Daily
Exposures Product Safety
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
Via Benzinga
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
Via Benzinga
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
Via Benzinga
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
The company previously had an accelerated approval for its IgA nephropathy treatment. 
Via Investor's Business Daily
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Preview For Travere Therapeutics
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024
TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
Exposures Product Safety
Where Travere Therapeutics Stands With Analysts
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback